Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic vaccine + allogeneic hematopoietic stem cells + cytotoxic lymphocytes (NeuroVita Clinic)
- Development stage
- Unknown
- Lead developer
- NeuroVita Clinic
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Stem Cell Therapies → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intrathecal, Subcutaneous
01
Overview
This personalized, multi-component immunotherapy regimen is developed by the NeuroVita Clinic for the treatment of brain metastases from breast cancer (BMBC). The protocol involves a first-line combination of three cell-based products: a dendritic cell vaccine (DV) pulsed with tumor-specific antigens derived from the patient's own brain metastasis sample; allogeneic haploidentical hematopoietic stem cells (HSCs) harvested from a related donor; and cytotoxic lymphocytes (CTLs) generated post-vaccination. The therapy aims to control tumor cell quantity and regulate the effector functions of tumor stem cells, potentially converting an acute lethal process into a chronic, manageable condition. The regimen utilizes intrathecal administration for HSCs and CTLs, and subcutaneous administration for the vaccine.
- Other names
- DV + allogeneic HSC + CTLProteome-based Personalized Immunotherapy
02
Targets
BTN3A1 (Butyrophilin 3A1/2A1 complex)pMHC (Peptide-MHC complex family)NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on dendritic vaccine + allogeneic hematopoietic stem cells + cytotoxic lymphocytes (NeuroVita Clinic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic vaccine + allogeneic hematopoietic stem cells + cytotoxic lymphocytes (NeuroVita Clinic).